3 results
First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measured by change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotide modifies…
The primary efficacy objective of the study is:* to evaluate whether rivaroxaban added to ASA is superior to ASA alone in reducingthe risk of major thrombotic vascular events (defined as MI, ischemic stroke, CVdeath, ALI, and major amputation of a…
Main goal:The main goal of the study is to show the feasibility of using Doppler US derived patient specific velocity profile in the abdominal aorta, carotid artery and femoral artery, in order to improve the Fluid-Structure-Interaction models of…